Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 4/20 | 0.95 |
| ▸ | MEN1 | O00255 | 9/20 | 0.95 |
| ▸ | THRB | P10828 | 9/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.95 |
| ▸ | BLM | P54132 | 8/20 | 0.95 |
| ▸ | RECQL | P46063 | 7/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.95 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.95 |
| ▸ | MAPT | P10636 | 6/20 | 0.95 |
| ▸ | S100A4 | P26447 | 6/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.95 |
| ▸ | USP2 | O75604 | 4/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.95 |
| ▸ | PAX8 | Q06710 | 4/20 | 0.95 |
| ▸ | STAT6 | P42226 | 4/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.95 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxorubicin SCHEMBL28086230 | 1.00 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL4019285 | 1.00 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL147967 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL1030848 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL18263941 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL8183120 | 0.99 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL28183637 | 0.98 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL94408 | 0.98 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL13858183 | 0.98 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL28229817 | 0.97 | MEN1 (0.97) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591339-B2 | Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors | Ikena Oncology, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210253579-A1 | POLYMORPHIC COMPOUNDS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591339-B2 | Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors | AHR, ARNT, CYP1A1 | TOP2A 3380/4885MEN1 3645/4885THRB 327/4885 |
| US-20210253579-A1 | POLYMORPHIC COMPOUNDS AND USES THEREOF | AHR, ARNT, MTNR1B | TOP2A 4449/4885MEN1 4664/4885THRB 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.